Key result
Review outlines nucleic acid-based vaccine design strategies targeting T. cruzi surface antigens for Chagas disease.
Why the study?
Current treatments for Chagas disease have significant side effects, require long durations, and do not improve chronic cardiomyopathy, motivating the development of therapeutic vaccines.
This review highlights the potential of nucleic acid-based vaccines targeting T. cruzi surface antigens to prevent or treat Chagas disease and its chronic complications such as cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Chagas nucleic acid vaccines remain investigational; this review leaves open their role in preventing cardiomyopathy.
Chagas disease is caused by the protozoan Trypanosoma cruzi and is endemic to Central and South America. However, it has spread around the world and affects several million people. Treatment with currently available drugs cause several side effects and require long treatment times to eliminate the parasite, however, this does not improve the chronic effects of the disease such as cardiomyopathy. A therapeutic vaccine for Chagas disease may be able to prevent the disease and improve the chronic effects such as cardiomyopathy. This vaccine would be beneficial for both infected people and those which are at risk in endemic and non-endemic areas. In this article, we will review the surface antigens of T. cruzi, in order to choose those that are most antigenic and least variable, to design effective vaccines against the etiological agent of Chagas disease. Also, we discuss aspects of the design of nucleic acid-based vaccines, which have been developed and proven to be effective against the SARS-CoV-2 virus. The role of co-adjuvants and delivery carriers is also discussed. We present an example of a chimeric trivalent vaccine, based on experimental work, which can be used to design a vaccine against Chagas disease.
No takes yet. Share an insight, caveat, or question.
Maldonado et al. (2022) conducted a review in Chagas disease. Nucleic acid-based vaccines was evaluated. This review discusses T. cruzi surface antigens and nucleic acid-based vaccine design strategies, presenting an example of a chimeric trivalent vaccine for Chagas disease.
Synapse has enriched 10 related papers. Consider them for comparative context: